Fig. 4
AIB5P enhances bone formation in vivo. Six mice in each group were administered AIB5P or vehicle (100 μg·kg−1, every 3 days, intravenous, total 1.5 months). Femurs were collected for further experiments. a High-magnification calcein and xylenol orange double labeling in femurs. Bar = 100 μm. The distance between the two fluorescent lines shows the amount of new bone deposition. b Quantification of the mineral apposition rate (MAR) and the bone formation rate per bone surface (BFR/BS) value. n = 6. c, d von Kossa staining and relative quantification of femur sections. Bar, 200 μm. Samples from six mice were used for statistics. e, f Representative anti-DMP1 IHC staining images and semiquantification. Samples from six mice were used for statistics. g Representative micro-CT of mouse femurs. Upper, longitudinal transverse sections at midshaft scans. Bar, 1 mm. Middle, trabecular bone underneath the growth plate. Bar, 500 μm. Lower, cortical bone. Bar, 500 μm. h Quantification analysis of micro-CT. Bone material density (BMD), bone volume per tissue volume (BV/TV), trabecular bone numbers (Tb.N), trabecular bone space (Tb.Sp) and trabecular bone thickness (Tb.Th) of trabecular bone compared between the vehicle control and AIB5P groups. BV/TV of the cortical bone was also compared. n = 6
